Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 2a, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression

Next Previous
X
Search
Trial Profile

An Open-Label, Phase 2a, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 5 Methoxy N N Dimethyltryptamine (Primary)
  • Indications Depression; Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Beckley Psytech

    • Most Recent Events

    • 24 Apr 2024 According to an ATAI Life Sciences media release, initial results from this trial are expected in H1 2025.
    • 24 Apr 2024 According to an ATAI Life Sciences media release, the first patient has been dosed in Part 2 of Beckley Psytech's Phase 2a study, evaluating BPL-003 (intranasal 5-MeO-DMT) in patients living with Treatment Resistant Depression (TRD).
    • 27 Mar 2024 Positive initial results from this Phase 2a open label study of BPL-003 (Intranasal 5-MeO-DMT) in treatment resistant depression presented in a Beckley Psytech media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top